These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34946246)

  • 1. Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
    Ricci AD; Rizzo A
    Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Targeted Therapies for Advanced Cholangiocarcinoma.
    Rizzo A; Brandi G
    Medicina (Kaunas); 2021 Feb; 57(3):. PubMed ID: 33652960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
    Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
    Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.
    Ten Haaft BH; Pedregal M; Prato J; Klümpen HJ; Moreno V; Lamarca A
    Eur J Cancer; 2024 Mar; 199():113564. PubMed ID: 38266541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
    Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
    Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholangiocarcinoma miscoding in hepatobiliary centres.
    Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.
    Loilome W; Namwat N; Jusakul A; Techasen A; Klanrit P; Phetcharaburanin J; Wangwiwatsin A
    Recent Results Cancer Res; 2023; 219():53-90. PubMed ID: 37660331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The present roles and future perspectives of Interleukin-6 in biliary tract cancer.
    Zhou M; Na R; Lai S; Guo Y; Shi J; Nie J; Zhang S; Wang Y; Zheng T
    Cytokine; 2023 Sep; 169():156271. PubMed ID: 37331095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in immunotherapy for biliary tract cancers.
    Zhao Y; Yang M; Feng J; Wang X; Liu Y
    Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical Resection Alone is Associated With Higher Long-Term Survival Than Multiagent Chemotherapy Alone for Patients With Localized Biliary Tract Cancers.
    Elshami M; Ammori JB; Hardacre JM; Selfridge JE; Bajor D; Mohamed A; Chakrabarti S; Mahipal A; Winter JM; Ocuin LM
    J Surg Res; 2024 Mar; 295():705-716. PubMed ID: 38141457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapies for Perihilar Cholangiocarcinoma.
    Gray S; Lamarca A; Edeline J; Klümpen HJ; Hubner RA; McNamara MG; Valle JW
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cholangiocarcinoma-diagnosis, classification, and molecular alterations].
    Goeppert B
    Pathologe; 2020 Sep; 41(5):488-494. PubMed ID: 32757029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
    Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
    Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.
    Schramm C; Sapuk A; Hoyer D; Radünz S; Schmidt H
    Z Gastroenterol; 2024 Jan; 62(1):37-42. PubMed ID: 38195106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
    Tang TY; Nichetti F; Kaplan B; Lonardi S; Pietrantonio F; Salvatore L; Vivaldi C; Rimassa L; de Braud F; Rizzato MD; Pavlick D; Chu R; Danner De Armas A; Sharaf R; Sokol E; Rodon Ahnert J; Ross JS; Javle M; Niger M
    Clin Cancer Res; 2023 Dec; 29(23):4853-4862. PubMed ID: 37773629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future is here-targeted therapies are coming of age in biliary tract cancers.
    Neureiter D; Ocker M
    Chin Clin Oncol; 2023 Jun; 12(3):20. PubMed ID: 37211774
    [No Abstract]   [Full Text] [Related]  

  • 20. What are the key challenges in the pharmacological management of cholangiocarcinoma?
    Ledenko M; Patel T
    Expert Opin Pharmacother; 2022 Apr; 23(5):531-533. PubMed ID: 34866539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.